TaiwanJ Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

TaiwanJ Pharmaceuticals has been growing earnings at an average annual rate of 12.3%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been declining at an average rate of 24.5% per year.

Key information

12.3%

Earnings growth rate

15.1%

EPS growth rate

Biotechs Industry Growth	12.2%
Revenue growth rate	-24.5%
Return on equity	-48.4%
Net Margin	n/a
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth

Apr 14

Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?

Dec 29

Revenue & Expenses Breakdown

How TaiwanJ Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:6549 Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	0	-28	16	16
31 Mar 24	11	-17	16	15
31 Dec 23	23	-6	15	14
30 Sep 23	30	-38	20	12
30 Jun 23	38	-71	25	10
31 Mar 23	27	-82	25	11
31 Dec 22	15	-92	24	13
30 Sep 22	8	-60	18	15
30 Jun 22	1	-27	12	17
31 Mar 22	11	-20	13	17
31 Dec 21	22	-12	14	18
30 Sep 21	22	-14	14	19
30 Jun 21	22	-15	15	20
31 Mar 21	11	-29	15	23
31 Dec 20	0	-42	14	26
30 Sep 20	0	-47	16	34
30 Jun 20	0	-51	17	42
31 Mar 20	31	-28	20	34
31 Dec 19	62	-5	22	26
30 Sep 19	62	-76	21	29
30 Jun 19	62	-147	21	31
31 Mar 19	31	-193	20	61
31 Dec 18	0	-238	20	91
30 Sep 18	0	-195	20	112
30 Jun 18	0	-152	20	132
31 Mar 18	0	-169	21	149
31 Dec 17	0	-186	21	166
30 Sep 17	0	-210	22	191
30 Jun 17	0	-234	24	215
31 Mar 17	0	-228	25	209
31 Dec 16	0	-223	25	202
30 Sep 16	0	-199	25	182
30 Jun 16	0	-176	25	161
31 Mar 16	0	-159	24	146
31 Dec 15	0	-142	22	132
30 Sep 15	0	-128	24	109
30 Jun 15	0	-114	25	87
31 Mar 15	0	-106	24	80

Quality Earnings: 6549 is currently unprofitable.

Growing Profit Margin: 6549 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 6549 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare 6549's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6549 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).

Return on Equity

High ROE: 6549 has a negative Return on Equity (-48.39%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/17 19:21
End of Day Share Price	2025/01/17 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TaiwanJ Pharmaceuticals Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution